Alnylam Book Value Per Share from 2010 to 2025

ALNY Stock

USD 278.25 1.94 0.70%

Alnylam Pharmaceuticals Book Value Per Share yearly trend continues to be fairly stable with very little volatility. Book Value Per Share is likely to outpace its year average in 2025. Book Value Per Share is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of Alnylam Pharmaceuticals according to its financial statements. View All Fundamentals

Book Value Per Share

First Reported

2010-12-31

Previous Quarter

(1.59)

Current Value

(1.51)

Quarterly Volatility

8.51425894

Credit Downgrade

Yuan Drop

Covid

Check Alnylam Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Alnylam Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 65.3 M, Interest Expense of 146.4 M or Other Operating Expenses of 2.5 B, as well as many indicators such as Price To Sales Ratio of 11.18, Dividend Yield of 0.0 or Days Sales Outstanding of 63.31. Alnylam financial statements analysis is a perfect complement when working with Alnylam Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of Alnylam Pharmaceuticals Correlation against competitors.

For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.

Latest Alnylam Pharmaceuticals' Book Value Per Share Growth Pattern

Below is the plot of the Book Value Per Share of Alnylam Pharmaceuticals over the last few years. It is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements. Alnylam Pharmaceuticals' Book Value Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Alnylam Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 0.25 X

10 Years Trend

Very volatile

Compare to Others All Fundamentals

Book Value Per Share

Timeline

Alnylam Book Value Per Share Regression Statistics

	Arithmetic Mean	5.47
	Coefficient Of Variation	155.71
	Mean Deviation	6.82
	Median	4.97
	Standard Deviation	8.51
	Sample Variance	72.49
	Range	33.5287
	R-Value	(0.04)
	Mean Square Error	77.52
	R-Squared	0
	Significance	0.87
	Slope	(0.08)
	Total Sum of Squares	1,087

Alnylam Book Value Per Share History

	2025	-1.51
	2024	-1.59
	2023	-1.77
	2022	-1.3
	2021	4.97
	2020	8.84
	2019	13.17

Other Fundumenentals of Alnylam Pharmaceuticals

Tangible Book Value Per Share

Alnylam Pharmaceuticals Book Value Per Share component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Total Liab	Total Current Assets	Property Plant Equipment	Current Deferred Revenue	Long Term Debt	Short Term Debt	Intangible Assets	Net Receivables	Common Stock	Net Tangible Assets	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Long Term Debt Total	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		-0.24	0.71	-0.97	0.84	0.97	0.93	0.99	0.96	0.37	0.88	0.49	0.86	0.9	0.82	-0.26	0.99	-0.62	-0.6	0.83	-0.85	-0.9	0.57	0.9
Total Stockholder Equity	-0.24		-0.74	0.33	-0.12	-0.25	-0.57	-0.23	-0.26	0.26	-0.62	0.02	-0.49	-0.59	0.11	1.0	-0.16	-0.39	0.18	-0.7	-0.04	0.47	-0.63	-0.53
Net Debt	0.71	-0.74		-0.72	0.49	0.75	0.87	0.69	0.72	0.03	0.88	0.34	0.91	0.9	0.37	-0.74	0.67	-0.09	-0.49	0.88	-0.5	-0.79	0.64	0.85
Retained Earnings	-0.97	0.33	-0.72		-0.88	-0.95	-0.94	-0.95	-0.97	-0.32	-0.9	-0.53	-0.85	-0.89	-0.83	0.35	-0.96	0.56	0.65	-0.85	0.86	0.96	-0.56	-0.9
Accounts Payable	0.84	-0.12	0.49	-0.88		0.82	0.76	0.82	0.88	0.24	0.75	0.47	0.64	0.69	0.8	-0.15	0.88	-0.62	-0.5	0.67	-0.79	-0.81	0.34	0.7
Short Term Investments	0.97	-0.25	0.75	-0.95	0.82		0.92	0.96	0.97	0.39	0.86	0.51	0.86	0.88	0.78	-0.27	0.97	-0.54	-0.71	0.8	-0.9	-0.88	0.55	0.88
Total Liab	0.93	-0.57	0.87	-0.94	0.76	0.92		0.92	0.91	0.21	0.97	0.41	0.91	0.98	0.65	-0.59	0.89	-0.39	-0.57	0.96	-0.71	-0.94	0.71	0.96
Total Current Assets	0.99	-0.23	0.69	-0.95	0.82	0.96	0.92		0.93	0.3	0.89	0.46	0.86	0.91	0.81	-0.25	0.97	-0.65	-0.56	0.84	-0.83	-0.88	0.61	0.89
Property Plant Equipment	0.96	-0.26	0.72	-0.97	0.88	0.97	0.91	0.93		0.41	0.86	0.62	0.87	0.86	0.8	-0.28	0.98	-0.53	-0.72	0.8	-0.91	-0.94	0.45	0.89
Current Deferred Revenue	0.37	0.26	0.03	-0.32	0.24	0.39	0.21	0.3	0.41		0.07	0.59	0.16	0.09	0.4	0.25	0.36	-0.25	-0.33	0.02	-0.4	-0.18	0.05	0.26
Long Term Debt	0.88	-0.62	0.88	-0.9	0.75	0.86	0.97	0.89	0.86	0.07		0.4	0.89	0.98	0.61	-0.64	0.85	-0.36	-0.5	0.99	-0.64	-0.91	0.74	0.93
Short Term Debt	0.49	0.02	0.34	-0.53	0.47	0.51	0.41	0.46	0.62	0.59	0.4		0.51	0.37	0.47	0.01	0.57	-0.32	-0.52	0.35	-0.59	-0.49	0.03	0.48
Intangible Assets	0.86	-0.49	0.91	-0.85	0.64	0.86	0.91	0.86	0.87	0.16	0.89	0.51		0.94	0.59	-0.49	0.85	-0.37	-0.59	0.87	-0.71	-0.9	0.52	0.9
Net Receivables	0.9	-0.59	0.9	-0.89	0.69	0.88	0.98	0.91	0.86	0.09	0.98	0.37	0.94		0.61	-0.6	0.86	-0.39	-0.51	0.97	-0.65	-0.9	0.73	0.94
Common Stock	0.82	0.11	0.37	-0.83	0.8	0.78	0.65	0.81	0.8	0.4	0.61	0.47	0.59	0.61		0.08	0.84	-0.79	-0.47	0.53	-0.8	-0.76	0.39	0.7
Net Tangible Assets	-0.26	1.0	-0.74	0.35	-0.15	-0.27	-0.59	-0.25	-0.28	0.25	-0.64	0.01	-0.49	-0.6	0.08		-0.18	-0.35	0.17	-0.71	-0.02	0.49	-0.64	-0.55
Capital Surpluse	0.99	-0.16	0.67	-0.96	0.88	0.97	0.89	0.97	0.98	0.36	0.85	0.57	0.85	0.86	0.84	-0.18		-0.64	-0.65	0.78	-0.9	-0.9	0.46	0.87
Deferred Long Term Liab	-0.62	-0.39	-0.09	0.56	-0.62	-0.54	-0.39	-0.65	-0.53	-0.25	-0.36	-0.32	-0.37	-0.39	-0.79	-0.35	-0.64		0.12	-0.28	0.56	0.42	-0.14	-0.38
Long Term Investments	-0.6	0.18	-0.49	0.65	-0.5	-0.71	-0.57	-0.56	-0.72	-0.33	-0.5	-0.52	-0.59	-0.51	-0.47	0.17	-0.65	0.12		-0.45	0.85	0.67	-0.16	-0.57
Long Term Debt Total	0.83	-0.7	0.88	-0.85	0.67	0.8	0.96	0.84	0.8	0.02	0.99	0.35	0.87	0.97	0.53	-0.71	0.78	-0.28	-0.45		-0.55	-0.87	0.78	0.92
Short Long Term Debt	-0.85	-0.04	-0.5	0.86	-0.79	-0.9	-0.71	-0.83	-0.91	-0.4	-0.64	-0.59	-0.71	-0.65	-0.8	-0.02	-0.9	0.56	0.85	-0.55		0.8	-0.22	-0.69
Net Invested Capital	-0.9	0.47	-0.79	0.96	-0.81	-0.88	-0.94	-0.88	-0.94	-0.18	-0.91	-0.49	-0.9	-0.9	-0.76	0.49	-0.9	0.42	0.67	-0.87	0.8		-0.54	-0.93
Net Working Capital	0.57	-0.63	0.64	-0.56	0.34	0.55	0.71	0.61	0.45	0.05	0.74	0.03	0.52	0.73	0.39	-0.64	0.46	-0.14	-0.16	0.78	-0.22	-0.54		0.74
Capital Stock	0.9	-0.53	0.85	-0.9	0.7	0.88	0.96	0.89	0.89	0.26	0.93	0.48	0.9	0.94	0.7	-0.55	0.87	-0.38	-0.57	0.92	-0.69	-0.93	0.74

Click cells to compare fundamentals

About Alnylam Pharmaceuticals Financial Statements

Alnylam Pharmaceuticals investors use historical fundamental indicators, such as Alnylam Pharmaceuticals' Book Value Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Alnylam Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Book Value Per Share	(1.59)	(1.51)
Tangible Book Value Per Share	(6.62)	(6.29)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

EBR	Centrais Electricas Brasileiras
HE	Hawaiian Electric Industries
VFC	VF Corporation

Additional Tools for Alnylam Stock Analysis

When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC